View Older Stories
-
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,
-
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti,
-
UBS Downgrades Procept BioRobotics Corp (PRCT) to Neutral
-
Piper Sandler: 'Should HTFL & PRCT Be Down Post OPPS? What Will It Take for BSX to Catch a Bid?'
-
Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
-
Evercore ISI Starts Procept BioRobotics Corp (PRCT) at Outperform
-
Leerink Downgrades Procept BioRobotics Corp (PRCT) to Market Perform
-
PROCEPT BioRobotics completes prostate cancer study enrollment
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q1 EPS by 112c
-
PROCEPT BioRobotics Corporation (PRCT) 4K contracts of May 20 puts trade, share price down 3.8%
-
TD Cowen on Procept BioRobotics Corp (PRCT): 'In-Line Q1 Should Fuel Stock Rebound'
-
PROCEPT BioRobotics launches HYDROS robotic system internationally
-
Baird Starts Procept BioRobotics Corp (PRCT) at Neutral
-
Procept BioRobotics Corp (PRCT) PT Lowered to $30 at Truist Securities
-
TD Cowen on Procept BioRobotics Corp (PRCT): 'We are constructive after the big stock decline'
-
Procept BioRobotics Corp (PRCT) PT Lowered to $28 at Piper Sandler
-
Oppenheimer Downgrades Procept BioRobotics Corp (PRCT) to Perform
-
Procept BioRobotics Corp (PRCT) PT Lowered to $34 at Wells Fargo
-
BofA Securities Downgrades Procept BioRobotics Corp (PRCT) to Underperform
-
PROCEPT BioRobotics (PRCT) Misses Q4 EPS by 21c, Offers Guidance
-
PROCEPT BioRobotics Corporation (PRCT) 4500 contracts of March 30 calls trade
-
UBS Starts Procept BioRobotics Corp (PRCT) at Buy
-
BofA Securities Downgrades Procept BioRobotics Corp (PRCT) to Neutral
-
TD Cowen Cuts Procept BioRobotics Corp (PRCT) Stock PT, But Sees Continued Upside
-
Procept BioRobotics Corp (PRCT) PT Lowered to $55 at Leerink Partners
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q3 EPS by 3c, provides guidance
-
Oppenheimer Upgrades Procept BioRobotics Corp (PRCT) to Outperform
-
Procept BioRobotics Corp (PRCT) PT Lowered to $58 at Wells Fargo
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q2 EPS by 6c
-
Oppenheimer Reiterates Perform Rating on Procept BioRobotics Corp (PRCT)
-
BTIG Reiterates Neutral Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics names Larry Wood as new CEO
-
BofA Securities Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Oppenheimer Starts Procept BioRobotics Corp (PRCT) at Perform
-
Truist Securities Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Procept BioRobotics Corp (PRCT) PT Lowered to $90 at Leerink Partners
-
Piper Sandler on Procept BioRobotics Corp (PRCT): 'Compelling Setup Ahead of Near-Term Catalysts'
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
PROCEPT BioRobotic (PRCT): WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
-
Jefferies Reiterates Hold Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Misses Q4 EPS by 1c
-
MedTech sector outlook for 2025: Truist Securities
-
Spruce Point short PROCEPT BioRobotics Corporation (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Mentioned as Short at Spruce Point
-
Spruce Point short PROCEPT BioRobotics Corporation (PRCT)
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Morgan Stanley Starts Procept BioRobotics Corp (PRCT) at Overweight, PT $105
-
Jefferies Starts Procept BioRobotics Corp (PRCT) at Hold
-
PROCEPT BioRobotics Corporation (PRCT) Prices 1.92M Share Offering at $91/sh
-
Procept BioRobotics Corp (PRCT) PT Raised to $105 at Truist Securities

